Xenetic Biosciences (XEN)

Xenetic Biosciences plc, formerly Lipoxen plc, is a holding company engaged in development of drug and vaccine delivery systems and products in fields of protein drugs, vaccines and oncology. The Company’s technology platforms include PolyXen for extending efficacy and half life of biologic drugs; ImuXen for creating new vaccines and improving existing vaccines, and OncoHist for novel mode of action drugs for oncology therapies. It has drug and vaccine programs with three products in human clinical development, such as ErepoXen, which is a long-acting formulation for treatment of anaemia in both End Stage Renal Disease patients and for those undergoing chemotherapy; OncoHist, which is a recombinant human histone H1.3 molecule in Phase I clinical trials in Russia for refractory Acute Myeloid Leukaemia and Non Hodgkin's Lymphoma, and SuliXen, which is insulin for both treatment of diabetes and for central nervous system condition. On January 17, 2012, the Company acquired SymbioTec GmbH.

Directors: M. Scott Maguire (CEO) , Colin Hill (CFO) 67, Gregory Gregoriadis (CSO) ,

No. of Employees: 15 No. of Shareholders: n/a

Last Annual	December 31st, 2011
Last Interim	June 30th, 2012
Shares in Issue	407,875,427
Free Float	107.6m (26.4%)

Sector	Healthcare
Industry	Biotechnology & Medical Research
Index	FTSE Aim All Share,
Exchange	London Stock Exchange (AIM)
Eligible for	an ISA? a SIPP?